Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Depreciation and Depletion (2016 - 2025)

Capricor Therapeutics has reported Depreciation and Depletion over the past 12 years, most recently at $502587.0 for Q4 2025.

  • Quarterly results put Depreciation and Depletion at $502587.0 for Q4 2025, up 33.77% from a year ago — trailing twelve months through Dec 2025 was $1.9 million (up 32.54% YoY), and the annual figure for FY2025 was $1.9 million, up 32.54%.
  • Depreciation and Depletion for Q4 2025 was $502587.0 at Capricor Therapeutics, up from $494725.0 in the prior quarter.
  • Over the last five years, Depreciation and Depletion for CAPR hit a ceiling of $502587.0 in Q4 2025 and a floor of $49054.0 in Q1 2021.
  • Median Depreciation and Depletion over the past 5 years was $265586.5 (2023), compared with a mean of $257989.9.
  • Biggest five-year swings in Depreciation and Depletion: skyrocketed 148.78% in 2023 and later increased 22.14% in 2024.
  • Capricor Therapeutics' Depreciation and Depletion stood at $78645.0 in 2021, then soared by 143.63% to $191602.0 in 2022, then skyrocketed by 60.55% to $307608.0 in 2023, then rose by 22.14% to $375705.0 in 2024, then soared by 33.77% to $502587.0 in 2025.
  • The last three reported values for Depreciation and Depletion were $502587.0 (Q4 2025), $494725.0 (Q3 2025), and $486278.0 (Q2 2025) per Business Quant data.